메뉴 건너뛰기




Volumn 389, Issue 10073, 2017, Pages 1025-1034

Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials

(19)  Costa, Francesco a,b,d   van Klaveren, David b,c   James, Stefan e   Heg, Dik f   Räber, Lorenz a   Feres, Fausto g   Pilgrim, Thomas a   Hong, Myeong Ki l   Kim, Hyo Soo h   Colombo, Antonio i,j   Steg, Philippe Gabriel k   Zanchin, Thomas a   Palmerini, Tullio m   Wallentin, Lars e   Bhatt, Deepak L n   Stone, Gregg W o   Windecker, Stephan a   Steyerberg, Ewout W b   Valgimigli, Marco a,b  


Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEMOGLOBIN; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

EID: 85015205271     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)30397-5     Document Type: Article
Times cited : (919)

References (32)
  • 1
    • 0035899289 scopus 로고    scopus 로고
    • Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
    • 1 Yusuf, S, Zhao, F, Mehta, SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001), 494–502.
    • (2001) N Engl J Med , vol.345 , pp. 494-502
    • Yusuf, S.1    Zhao, F.2    Mehta, S.R.3
  • 2
    • 70149101223 scopus 로고    scopus 로고
    • Ticagrelor versus clopidogrel in patients with acute coronary syndromes
    • 2 Wallentin, L, Becker, RC, Budaj, A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361 (2009), 1045–1057.
    • (2009) N Engl J Med , vol.361 , pp. 1045-1057
    • Wallentin, L.1    Becker, R.C.2    Budaj, A.3
  • 3
    • 36148983750 scopus 로고    scopus 로고
    • Prasugrel versus clopidogrel in patients with acute coronary syndromes
    • 3 Wiviott, SD, Braunwald, E, McCabe, CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007), 2001–2015.
    • (2007) N Engl J Med , vol.357 , pp. 2001-2015
    • Wiviott, S.D.1    Braunwald, E.2    McCabe, C.H.3
  • 4
    • 84929462814 scopus 로고    scopus 로고
    • Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials
    • 4 Navarese, EP, Andreotti, F, Schulze, V, et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ, 350, 2015, h1618.
    • (2015) BMJ , vol.350 , pp. h1618
    • Navarese, E.P.1    Andreotti, F.2    Schulze, V.3
  • 5
    • 84913619061 scopus 로고    scopus 로고
    • 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
    • 5 Windecker, S, Kolh, P, Alfonso, F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35 (2014), 2541–2619.
    • (2014) Eur Heart J , vol.35 , pp. 2541-2619
    • Windecker, S.1    Kolh, P.2    Alfonso, F.3
  • 6
    • 84994777362 scopus 로고    scopus 로고
    • 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
    • 6 Levine, GN, Bates, ER, Bittl, JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 68 (2016), 1082–1115.
    • (2016) J Am Coll Cardiol , vol.68 , pp. 1082-1115
    • Levine, G.N.1    Bates, E.R.2    Bittl, J.A.3
  • 7
    • 84918772240 scopus 로고    scopus 로고
    • Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents
    • 7 Mauri, L, Kereiakes, DJ, Yeh, RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371 (2014), 2155–2166.
    • (2014) N Engl J Med , vol.371 , pp. 2155-2166
    • Mauri, L.1    Kereiakes, D.J.2    Yeh, R.W.3
  • 8
    • 84964963457 scopus 로고    scopus 로고
    • Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention
    • 8 Yeh, RW, Secemsky, EA, Kereiakes, DJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA 315 (2016), 1735–1749.
    • (2016) JAMA , vol.315 , pp. 1735-1749
    • Yeh, R.W.1    Secemsky, E.A.2    Kereiakes, D.J.3
  • 9
    • 84916894797 scopus 로고    scopus 로고
    • Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial
    • 9 Pilgrim, T, Heg, D, Roffi, M, et al. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. Lancet 384 (2014), 2111–2122.
    • (2014) Lancet , vol.384 , pp. 2111-2122
    • Pilgrim, T.1    Heg, D.2    Roffi, M.3
  • 10
    • 84865334791 scopus 로고    scopus 로고
    • Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial
    • 10 Raber, L, Kelbaek, H, Ostojic, M, et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA 308 (2012), 777–787.
    • (2012) JAMA , vol.308 , pp. 777-787
    • Raber, L.1    Kelbaek, H.2    Ostojic, M.3
  • 11
    • 84856452781 scopus 로고    scopus 로고
    • Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study
    • 11 Gwon, HC, Hahn, JY, Park, KW, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 125 (2012), 505–513.
    • (2012) Circulation , vol.125 , pp. 505-513
    • Gwon, H.C.1    Hahn, J.Y.2    Park, K.W.3
  • 12
    • 84890373385 scopus 로고    scopus 로고
    • Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial
    • 12 Feres, F, Costa, RA, Abizaid, A, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 310 (2013), 2510–2522.
    • (2013) JAMA , vol.310 , pp. 2510-2522
    • Feres, F.1    Costa, R.A.2    Abizaid, A.3
  • 13
    • 84860135329 scopus 로고    scopus 로고
    • Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial
    • 13 Valgimigli, M, Campo, G, Monti, M, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 125 (2012), 2015–2026.
    • (2012) Circulation , vol.125 , pp. 2015-2026
    • Valgimigli, M.1    Campo, G.2    Monti, M.3
  • 14
    • 84867050148 scopus 로고    scopus 로고
    • A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)
    • 14 Kim, BK, Hong, MK, Shin, DH, et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 60 (2012), 1340–1348.
    • (2012) J Am Coll Cardiol , vol.60 , pp. 1340-1348
    • Kim, B.K.1    Hong, M.K.2    Shin, D.H.3
  • 15
    • 84918810121 scopus 로고    scopus 로고
    • Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial
    • 15 Colombo, A, Chieffo, A, Frasheri, A, et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol 64 (2014), 2086–2097.
    • (2014) J Am Coll Cardiol , vol.64 , pp. 2086-2097
    • Colombo, A.1    Chieffo, A.2    Frasheri, A.3
  • 16
    • 84923356619 scopus 로고    scopus 로고
    • Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates
    • 16 Valgimigli, M, Patialiakas, A, Thury, A, et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol 65 (2015), 805–815.
    • (2015) J Am Coll Cardiol , vol.65 , pp. 805-815
    • Valgimigli, M.1    Patialiakas, A.2    Thury, A.3
  • 17
    • 84949293093 scopus 로고    scopus 로고
    • Relation between hospital length of stay and quality of care in patients with acute coronary syndromes (from the American Heart Association's Get With the Guidelines—Coronary Artery Disease Data Set)
    • 17 Tickoo, S, Bhardwaj, A, Fonarow, GC, Liang, L, Bhatt, DL, Cannon, CP, Relation between hospital length of stay and quality of care in patients with acute coronary syndromes (from the American Heart Association's Get With the Guidelines—Coronary Artery Disease Data Set). Am J Cardiol 117 (2016), 201–205.
    • (2016) Am J Cardiol , vol.117 , pp. 201-205
    • Tickoo, S.1    Bhardwaj, A.2    Fonarow, G.C.3    Liang, L.4    Bhatt, D.L.5    Cannon, C.P.6
  • 18
    • 84964370865 scopus 로고    scopus 로고
    • Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS
    • 18 Baber, U, Mehran, R, Giustino, G, et al. Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS. J Am Coll Cardiol 67 (2016), 2224–2234.
    • (2016) J Am Coll Cardiol , vol.67 , pp. 2224-2234
    • Baber, U.1    Mehran, R.2    Giustino, G.3
  • 22
    • 84920572286 scopus 로고    scopus 로고
    • Comparing two correlated C indices with right-censored survival outcome: a one-shot nonparametric approach
    • 22 Kang, L, Chen, W, Petrick, NA, Gallas, BD, Comparing two correlated C indices with right-censored survival outcome: a one-shot nonparametric approach. Stat Med 34 (2015), 685–703.
    • (2015) Stat Med , vol.34 , pp. 685-703
    • Kang, L.1    Chen, W.2    Petrick, N.A.3    Gallas, B.D.4
  • 23
    • 38849091997 scopus 로고    scopus 로고
    • Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond
    • discussion 207–12.
    • 23 Pencina, MJ, D'Agostino, RB Sr, D'Agostino, RB Jr, Vasan, RS, Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27 (2008), 157–172 discussion 207–12.
    • (2008) Stat Med , vol.27 , pp. 157-172
    • Pencina, M.J.1    D'Agostino, R.B.2    D'Agostino, R.B.3    Vasan, R.S.4
  • 24
    • 84937548548 scopus 로고    scopus 로고
    • Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration
    • 24 Moons, KG, Altman, DG, Reitsma, JB, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med 162 (2015), W1–73.
    • (2015) Ann Intern Med , vol.162 , pp. W1-73
    • Moons, K.G.1    Altman, D.G.2    Reitsma, J.B.3
  • 25
    • 84867738043 scopus 로고    scopus 로고
    • The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day
    • 25 Angiolillo, DJ, The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs 72 (2012), 2087–2116.
    • (2012) Drugs , vol.72 , pp. 2087-2116
    • Angiolillo, D.J.1
  • 26
    • 84877975639 scopus 로고    scopus 로고
    • Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status
    • 26 Amin, AP, Bachuwar, A, Reid, KJ, et al. Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status. J Am Coll Cardiol 61 (2013), 2130–2138.
    • (2013) J Am Coll Cardiol , vol.61 , pp. 2130-2138
    • Amin, A.P.1    Bachuwar, A.2    Reid, K.J.3
  • 27
    • 84940050465 scopus 로고    scopus 로고
    • Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention
    • 27 Genereux, P, Giustino, G, Witzenbichler, B, et al. Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention. J Am Coll Cardiol 66 (2015), 1036–1045.
    • (2015) J Am Coll Cardiol , vol.66 , pp. 1036-1045
    • Genereux, P.1    Giustino, G.2    Witzenbichler, B.3
  • 28
    • 65549123030 scopus 로고    scopus 로고
    • Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) bleeding score
    • 28 Subherwal, S, Bach, RG, Chen, AY, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) bleeding score. Circulation 119 (2009), 1873–1882.
    • (2009) Circulation , vol.119 , pp. 1873-1882
    • Subherwal, S.1    Bach, R.G.2    Chen, A.Y.3
  • 29
    • 84979994198 scopus 로고    scopus 로고
    • Atherothrombotic risk stratification and the efficacy and safety of vorapaxar in patients with stable ischemic heart disease and previous myocardial infarction
    • 29 Bohula, EA, Bonaca, MP, Braunwald, E, et al. Atherothrombotic risk stratification and the efficacy and safety of vorapaxar in patients with stable ischemic heart disease and previous myocardial infarction. Circulation 134 (2016), 304–313.
    • (2016) Circulation , vol.134 , pp. 304-313
    • Bohula, E.A.1    Bonaca, M.P.2    Braunwald, E.3
  • 30
    • 0141455899 scopus 로고    scopus 로고
    • Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials
    • 30 Gurm, HS, Bhatt, DL, Lincoff, AM, et al. Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials. Heart 89 (2003), 1200–1204.
    • (2003) Heart , vol.89 , pp. 1200-1204
    • Gurm, H.S.1    Bhatt, D.L.2    Lincoff, A.M.3
  • 31
    • 84930144998 scopus 로고    scopus 로고
    • Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey
    • 31 Valgimigli, M, Costa, F, Byrne, R, Haude, M, Baumbach, A, Windecker, S, Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey. EuroIntervention 11 (2015), 68–74.
    • (2015) EuroIntervention , vol.11 , pp. 68-74
    • Valgimigli, M.1    Costa, F.2    Byrne, R.3    Haude, M.4    Baumbach, A.5    Windecker, S.6
  • 32
    • 84975896253 scopus 로고    scopus 로고
    • The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study
    • 32 Hijazi, Z, Oldgren, J, Lindback, J, et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet 387 (2016), 2302–2311.
    • (2016) Lancet , vol.387 , pp. 2302-2311
    • Hijazi, Z.1    Oldgren, J.2    Lindback, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.